EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSLBEG00000010240
Gene Symbol: PIK3R3
1 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSLBEG00000026446
Gene Symbol: PIK3R5
3 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSLBEG00000000976
Gene Symbol: PIK3R5
3 Cross references
199 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSLBEG00000023586
Gene Symbol: LOC109990367
3 Cross references
232 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSLBEG00000020285
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSLBEG00000023793
Gene Symbol: PLG
3 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSLBEG00000024742
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSLBEG00000000948
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSLBEG00000020651
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSLBEG00000027586
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSLBEG00000022973
Gene Symbol: LOC109982347
3 Cross references
203 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSLBEG00000008688
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).